Alemtuzumab Biosimilar - Research Grade

Target: CD52.

Specificity: Detects human CD52. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Alemtuzumab.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background: Alemtuzumab biosimilar is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) directed against the 21-28 kD cell surface glycoprotein, CD52, is an IgG1 kappa antibody with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody. The alemtuzumab biosimilar has an approximate molecular weight of 150 kD and is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium.

Concentration: 1.0 - 5.0 mg/ml.

Formulation: Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Purity: >95% by SDS-PAGE and HPLC.

Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.